BREAKING NEWS: New drug approved by the FDA for Duchenne muscular dystrophy. Learn more about this new treatment option.

Medical Educational Resource

We're accelerating the delivery of treatments and cures.

Transition from Pediatric to Adult Care in Muscular Dystrophies: DMD, LGMD, FSHD, Myotonic Dystrophy

Activity Snapshot

Activity Type: 
On-Demand Webinar
Release Date: 
Monday, February 24, 2020
Sponsor Information: 

This activity has received an educational grant from PTC Therapeutics Inc.

Faculty

John Brandsema, MD
John Brandsema, MD
Neuromuscular Section Head, Division of Neurology
Children’s Hospital of Philadelphia
Lauren Elman, MD
Lauren Elman, MD
Associate Professor of Neurology
Perelman School of Medicine at the University of Pennsylvania
Vanessa Battista, MS, RN, CPNP-PC, CHPPN
Vanessa Battista, MS, RN, CPNP-PC, CHPPN
Nurse Practitioner
The Children's Hospital of Philadelphia Neuromuscular Program
Sarah Clark Stoney, MSW, LSW
Sarah Clark Stoney, MSW, LSW
Licensed Medical Social Worker (Subspecialty Outpatient Neurology Social Worker)
The Children’s Hospital of Philadelphia
Cynthia Clyburn, LSW
Cynthia Clyburn, LSW
Licensed Social Worker
Hospital of the University of Pennsylvania, Department of Neurology
Transition from Pediatric to Adult Care in Muscular Dystrophies: DMD, LGMD, FSHD, Myotonic Dystrophy
Activity Overview: 

The transition from pediatric to adult care is a challenging time for patients with neuromuscular disease and their families, as well as for providers. Increased use of disease-modifying treatments will likely lead to increased numbers of patients going through the transition process, and providers need to be aware of best practices to ensure this process is beneficial to all stakeholders. Part two of this three-part series will focus on Duchenne and other muscular dystrophies.